Merck scraps £1bn expansion in the UK over lack of state investment

The United States Giant Merck says that the government does not invest enough in the sector, saying that the UK operations are expanded to the planned £ 1 billion.

The multinational enterprise, known as the MSD in Europe, said that it would carry the research of life sciences to the USA and will cut more than 100 UK business and accuse developing governments for reducing the value of innovative drugs.

The government spokesman defended science and research investments, but admitted that it was “more work”.

Pharmaceutical companies are focusing on American investments after US President Donald Trump, including US President Donald Trump’s sky statutes, including the sky regulations for drug imports.

The MSD started construction on the London King’s Cross site, which will be completed until 2027, but no longer plans to occupy it.

The company will also evacuate its laboratories at the London Bioscience Innovation Center and Francis Crick Institute by the end of the year, causing 125 work loss.

The decision of the drug company, the decision, “British life science industry and lack of investment in the industry and the audience by successive British governments in general to evaluate innovative drugs and vaccines in general,” he said.

Richard Torbett, General Manager of the British Pharmaceutical Industry Association, said the decision was “an incredible coup”.

“Indeed, companies should see things that direct companies to make these difficult decisions and what they can do to return to this round,” we should see the Money to Wake program. ” He said.

“The lack of competitiveness of England is the biggest thing that directs the decision.”

He said: “We have great powerful aspects in this country – we have fantastic academic institutions, good infrastructure, magnificent medical research aid organizations – but there is a systematic insufficient investment in the products coming out of innovation.”

The MSD is the latest pharmaceutical company that abandons or reduces investment plans in the UK.

Astrazeneca in January It moved away from 450 million pounds of investment plans Earlier this year, it reduced government support in the expansion of a vaccine production facility in Merseyside.

Another drug giant British boss warned that NHS patients will lose access to cut -edged treatments last month. It was “to a large extent”.

Johan Kahlstrom from Norvartis said the company’s UK market has been “in the country because of the” declining competitiveness “in the country.

Industrial sources, BBC, the industry, focusing on the point of intersection between life sciences and artificial intelligence, Kings Cross has suffered a major financing in the center around the center.

They returned to their allegations that the decision was connected to the ongoing negotiations on the drug prices of the industry to make NHS more approved by NHS and to pay more for drugs.

The current pricing regime was determined and accepted by drug companies in 2023 less than 18 months.

Since then, drug companies have influenced their ability to reducing drug prices for US customers from Trump administration and making more investment in the United States – this has affected their ability to invest elsewhere.

In August Interview with CNBCTrump suggested that drug tariffs imported to the United States can reach up to 250%.

The threat watched an executive order signed by the President in May.

David Roblin, General Manager of Therapeutics, a London -based biotechnology company relationship, told BBC that the foundations that pushed MSD to invest in England in the first place have not changed.

“The academic environment in the United Kingdom continues to produce innovative ideas and people to work with these ideas that attract foreign investments.” He said.

“The environment to do research is still extraordinary: We have great academicians, NHS provides a research platform, for example, Biobank proves that there are real attractions for companies like me.” He said.

Dr. Roblin, the changing thing, the US in the United States that the political view of the political view, “the US continues to be the biggest market for drugs in the world,” he said.

The spokesman of the Department of Industry, Science and Technology said: “Britain has become the most attractive place to invest in the world, but we know that there is more work to do.

“We know that this will happen for MSD employees and the government will be ready to support the affected.”